Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for a Phase I trial for ASC50 for the ...

By elevating patient perspectives from an afterthought to a core part of the process, payers can create a system that aligns ...

Personalis, Inc. , a leader in advanced genomics for precision oncology, announced multiple presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting next week in Chicago, ...

It is predicted that the first new drug developed by artificial intelligence (AI) may be commercialized in 2030. Alex ...

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar ...

Aurinia Pharmaceuticals Inc. (Aurinia or the Company), today announced that a post-hoc analysis of the 52-week, Phase 3 AURORA 1 study showed that lupus nephritis (LN) patients who received triple ...

Discover how thyroid disorders affect your hair growth cycle, why testing matters, and what to expect during recovery from ...

Acids are out, gentle skincare is in. With the help of expert dermatologists, we dive into why gentle skincare can be the ...

Discover commonly overlooked causes of allergic reactions and rashes, from hidden household allergens to unexpected food ...

Kaddis said insurers are locked in a cat-and-mouse game with drugmakers as the insurance sector invests in biosimilars and ...

Long before global beauty brands caught on, ancient traditions were tapping into the healing powers of local botanicals.

Pyzchiva® is a key biosimilar value driver for the Sandoz growth strategy. It has been launched in 23 markets in Europe. The autoinjector is now available in Spain and will continue to roll out across ...